Hikma Pharmaceuticals has named ViiV Healthcare finance chief Rebecca Hall as its next chief financial officer, completing a Leadership reshuffle that began alongside a cautious 2026 outlook in February.
Hikma Pharmaceuticals (LSE:HIK) has filled one of the most closely watched gaps in its senior team. On 24 September the generic and branded medicines group announced that Rebecca Hall will join as chief financial officer and an executive director in the first quarter of 2027. The appointment follows a year in which the company has reorganised its leadership, cut its growth expectations and sought to rebuild investor confidence through Buybacks and steady Dividend increases.
An experienced pharmaceutical finance chief
Ms Hall is currently senior vice-president and chief financial officer of ViiV Healthcare, the HIV specialist majority owned by GSK. She has more than 20 years of experience in the pharmaceutical industry, including 14 years at GSK in commercial, strategic, corporate and Supply Chain Finance roles across the UK, Europe and emerging markets. She also served as chief of staff to GSK's group finance chief before moving to ViiV in 2018, where she rose from global finance controller to CFO in 2024.
Her arrival will allow Khalid Nabilsi, Hikma's long-serving finance chief, to step down from the board on 31 December 2026. He will remain with the group as deputy chief executive responsible for North America and Europe, a role created in February's restructuring.
A reshuffle born of a weak outlook
That restructuring was announced on 26 February alongside full-year 2025 results, when Hikma disappointed the market with guidance for 2026 Revenue growth of 2 to 4% and core operating profit of $720m to $770m, below market expectations at the time. The company also withdrew its medium-term group targets and its injectables Margin guidance. The shares fell 16% to 1,391p that day. Said Darwazah moved from executive chairman to focus solely on the chief executive role, Victoria Hull became chair, and Mazen Darwazah and Mr Nabilsi were named deputy chief executives.
Sentiment improved with the half-year results on 6 August. Group revenue rose 4% to $1,728m and core operating profit increased 9% to $405m. The Branded division led the way, with revenue up 15% to $502m, helped by Demand in the Middle East and North Africa. Injectables revenue was flat at $685m as a US product transition offset growth elsewhere, while Hikma Rx revenue slipped 1% to $520m but core operating profit in that unit rose 16%. The Interim Dividend was lifted 6% to 38 cents and management reiterated full-year guidance. The shares rose around 10% to 1,733p in early trading.
Capital returns and R&D focus
Hikma has also been returning cash. By the half-year stage it had bought back $227m of shares under its $250m programme launched in February, and regular transaction in own shares notices continued through August. Net Debt stood at $1,694m, equivalent to 1.9 times core EBITDA.
The next catalyst is a series of investor education sessions on R&D. Announced on 22 September, the three-part programme begins on 20 October with a session on group R&D, respiratory, nasal, semi-solid and liquid products, followed by solid orals in November and injectables in December. Hikma said it aspires to spend around 5 to 6% of revenue on R&D and that the sessions will not include new financial or trading information.
For investors, the key questions remain whether Injectables can return to growth and whether the company can deliver within its 2026 guidance range.






Please wait processing your request...